A Phase 4 interventional study of Sirolimus+MMF or MPS or AZA+Steroid and Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid in Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Terminated at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate whether conversion from cyclosporine, a calcineurin inhibitor (CI) to sirolimus (SRL) results in improved long-term renal function without a negative impact on safety or immunosuppressive efficacy, and to further examine the potential of SRL to reduce the severity and/or progression of chronic allograft nephropathy (CAN).
This open-label, randomized, parallel-group, comparative, outpatient study will be conducted in multiple centers in Taiwan.
The study will randomize approximately 120 patients. 80 patients will be randomized to the SRL therapy group (conversion from CI- to SRL-based immunosuppression: group A) and 40 patients to the CI therapy group (continued CI therapy: group B).
Dosage and Administration
SRL Therapy: At the time of randomization on day 1, each patient will have been receiving:
SRL will be added to the immunosuppressive regimen for Group A. Group B will continue on this CI immunosuppressive regimen.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sirolimus therapy
Drug: Sirolimus+MMF or MPS or AZA+Steroid
Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
Drug: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
The maintenance dose of: 1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day 2. AZA will not exceed 75 mg/day Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be: 1. continued for the entire 104-week period of randomized therapy 2. subsequently discontinued 3. restarted after discontinuation
Change in Glomerular Filtration Rate (GFR) Change From Baseline
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
Time frame: 104 weeks
Change in Glomerular Filtration Rate (GFR)
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
Time frame: Baseline and Week 24
Change in Glomerular Filtration Rate (GFR)
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
Time frame: Baseline and Week 52
Change in Glomerular Filtration Rate (GFR)
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
Time frame: Baseline and Week 104
Patient and Graft Survival
Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
Time frame: Week 24
Patient and Graft Survival
Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
Time frame: Week 52
Patient and Graft Survival
Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
Time frame: Week 104
Change From Baseline in Diastolic Blood Pressure at Week 24
Value at Week 24 minus value at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Diastolic Blood Pressure at Week 52
Value at Week 52 minus value at baseline.
Time frame: Baseline and Week 52
Change From Baseline in Diastolic Blood Pressure at Week 104
Value at Week 104 minus value at baseline.
Time frame: Baseline and Week 104
Change From Baseline in Systolic Blood Pressure at Week 24
Value at Week 24 minus value at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Systolic Blood Pressure at Week 52
Value at Week 52 minus value at baseline.
Time frame: Baseline and Week 52
Change From Baseline in Systolic Blood Pressure at Week 104
Value at Week 104 minus value at baseline.
Time frame: Baseline and Week 104
Change From Baseline in the Severity and Progression of Biopsy-Confirmed Chronic Allograft Nephropathy (CAN) at Week 104
Time frame: Baseline and Week 104
Occurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 52
Time frame: Weeks 52
Occurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 104
Time frame: Week 104
Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 24
Time frame: Week 24
Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 52
Time frame: Week 52
Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 104
Time frame: Week 104
Patients were recruited in Taiwan from April 2007 to May 2008.
| Milestone | Sirolimus (SRL) | Calcineurin Inhibitor (CI) |
|---|---|---|
| Started | 21 | 10 |
| Completed | 0 | 0 |
| Not completed | 21 | 10 |
| Withdrew: Adverse event | 8 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Premature termination | 13 | 9 |
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
No measurements were reported for this outcome.
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
No measurements were reported for this outcome.
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
No measurements were reported for this outcome.
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
No measurements were reported for this outcome.
Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
No measurements were reported for this outcome.
Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
No measurements were reported for this outcome.
Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
No measurements were reported for this outcome.
Value at Week 24 minus value at baseline.
No measurements were reported for this outcome.
Value at Week 52 minus value at baseline.
No measurements were reported for this outcome.
Value at Week 104 minus value at baseline.
No measurements were reported for this outcome.
Value at Week 24 minus value at baseline.
No measurements were reported for this outcome.
Value at Week 52 minus value at baseline.
No measurements were reported for this outcome.
Value at Week 104 minus value at baseline.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirolimus (SRL) | — | 6/21 (28.6%) | 78/21 (371.4%) |
| Calcineurin Inhibitor (CI) | — | 2/10 (20%) | 18/10 (180%) |
| Event | Sirolimus (SRL) | Calcineurin Inhibitor (CI) |
|---|---|---|
| Lens dislocationEye disorders | 0/21 | 1/10 |
| AppendicitisGastrointestinal disorders | 0/21 | 1/10 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/21 | 0/10 |
| Mechanical ileusGastrointestinal disorders | 1/21 | 0/10 |
| PyrexiaGeneral disorders | 1/21 | 0/10 |
| CellulitisGeneral disorders | 1/21 | 0/10 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/21 | 0/10 |
| Event | Sirolimus (SRL) | Calcineurin Inhibitor (CI) |
|---|---|---|
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 11/21 | 6/10 |
| Mouth ulcerationGastrointestinal disorders | 11/21 | 2/10 |
| HyperlipidaemiaMetabolism and nutrition disorders | 10/21 | 3/10 |
| AcneSkin and subcutaneous tissue disorders | 8/21 | 1/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/21 | 1/10 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/21 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 3/21 | 2/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/21 | 0/10 |
| Hepatic function abnormalHepatobiliary disorders | 3/21 | 0/10 |
| InsominaNervous system disorders | 3/21 | 0/10 |
| Age Continuous(years) | Sirolimus (SRL) | Calcineurin Inhibitor (CI) | Total |
|---|---|---|---|
| Mean | 46.8 ± 7.9 | 42.2 ± 13.9 | 43.3 ± 10.2 |
| Sex: Female, Male(Participants) | Sirolimus (SRL) | Calcineurin Inhibitor (CI) | Total |
|---|---|---|---|
| Female | 11 | 2 | 13 |
| Male | 10 | 8 | 18 |
The record gives a start of Apr 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyeth is now a wholly owned subsidiary of Pfizer →